- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05376150
Uno studio per valutare la sicurezza, la tollerabilità e l'efficacia di XEN1101 nel disturbo depressivo maggiore (X-NOVA)
Uno studio multicentrico proof-of-concept, randomizzato, in doppio cieco, controllato con placebo per valutare la sicurezza, la tollerabilità e l'efficacia di XEN1101 nel disturbo depressivo maggiore
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study is divided into 3 stages: Screening - up to 4 weeks duration; Treatment - 6 weeks duration; Follow-up - 4 weeks duration. The total study duration per subject is estimated to be approximately 14 weeks.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
California
-
Anaheim, California, Stati Uniti, 92805
- Advanced Research Center
-
Lafayette, California, Stati Uniti, 94549
- Sunwise Clinical Research, LLC
-
Pico Rivera, California, Stati Uniti, 90660
- California Neuropsychopharmacology Clinical Research Institute
-
Riverside, California, Stati Uniti, 92503
- Artemis Institute for Clinical Research
-
San Diego, California, Stati Uniti, 92103
- Artemis Institute for Clinical Research
-
-
Florida
-
Miami, Florida, Stati Uniti, 33014
- Meridian International Research
-
Miami, Florida, Stati Uniti, 33125
- Global Medical Institutes (GMI)
-
Miami, Florida, Stati Uniti, 33133
- CCM Clinical Reseach Group, LLC
-
-
Georgia
-
Decatur, Georgia, Stati Uniti, 30030
- i-Research, Atlanta
-
Marietta, Georgia, Stati Uniti, 30060
- Psych Atlanta, PC
-
Savannah, Georgia, Stati Uniti, 31405
- iResearch
-
-
Illinois
-
Elgin, Illinois, Stati Uniti, 60123
- Revive Research Institute, Inc.
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89102
- Altea Research
-
-
New Jersey
-
Marlton, New Jersey, Stati Uniti, 08009
- Hassman Research Institute
-
Toms River, New Jersey, Stati Uniti, 08755
- Bio Behavioral Health
-
-
New York
-
Cedarhurst, New York, Stati Uniti, 11516
- Neurobehavioral Research, Inc. (NBR)
-
New York, New York, Stati Uniti, 10036
- Manhattan Behavioral Medicine, PLLC
-
-
North Carolina
-
Raleigh, North Carolina, Stati Uniti, 27609
- Richard M Weisler and Association
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75231
- FutureSearch Trials of Dallas, LP
-
Plano, Texas, Stati Uniti, 75093
- AIM Trials
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
- Be properly informed of the nature and risks of the study and given written informed consent.
- Male or female, aged 18 through 65 years (inclusive) with a body mass index (BMI) ≤35 kg/m².
- Subject must meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for current MDD and currently in a moderate to severe major depressive episode (MDE), confirmed using the Mini International Neuropsychiatric Interview (MINI).
- Current MDE duration ≥2 months and <24 months at the time of screening.
- Current illness severity that is at least moderate, defined as a score of ≥20 on the HAM-D17 at screening and on Day 1.
- Score ≥20 on the SHAPS at screening and on Day1.
- Must be willing to comply with the study protocol for the full term of the study.
Key Exclusion Criteria:
- A primary psychiatric diagnosis other than MDD as defined by DSM-5 (comorbid anxiety disorders [including agoraphobia, generalized anxiety disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), and panic disorder] are allowed).
- Concomitant use of antidepressants and/or other disallowed pharmacotherapy (including benzodiazepines).
- History of schizophrenia or other psychotic disorder, MDD with psychotic features, bipolar I or II disorder, or MDD with mixed features.
- History of non-response to >1 antidepressant drug due to lack of efficacy in the current MDE.
- Failing >3 antidepressant drug trials, for any reason, in the current MDE.
- History of non-response to electroconvulsive therapy (ECT) in the past 10 years.
- Active suicidal plan/intent in the past 6 months, or more than 1 lifetime suicide attempt.
- Females who are pregnant, breastfeeding, or planning to become pregnant during the first administration of study drug until 3 months after the last dose of study drug.
- Meets criteria for a substance use disorder within the past 12 months, with the exception of tobacco use, and/or has a positive urine toxicology screen for drugs of abuse.
- Any medical condition or personal circumstance that, in the opinion of the investigator, exposes the subject to unacceptable risk by participating in the study or prevents adherence to the protocol.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: XEN1101 10 mg
During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 10 mg, orally with food, per day |
XEN1101 oral capsule |
|
Sperimentale: XEN1101 20 mg
During the double blind treatment period (42 days), subjects will take 1 capsule of XEN1101 20 mg, orally with food, per day |
XEN1101 oral capsule |
|
Comparatore placebo: placebo
During the double blind treatment period (42 days), subjects will take 1 capsule of placebo, orally with food, per day |
Placebo capsule |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score.
Lasso di tempo: From baseline to end of treatment (Week 6).
|
Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated, 10-item scale used to assess the severity of depressive symptoms. Each item is scored from 0 (normal/absent) to 6 (severe), yielding a total score ranging from 0 to 60, with higher scores indicating greater depression severity. MADRS total score change from baseline at week 6. |
From baseline to end of treatment (Week 6).
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Snaith-Hamilton Pleasure Scale (SHAPS) Score.
Lasso di tempo: From baseline to end of treatment (Week 6).
|
Snaith-Hamilton Pleasure Scale (SHAPS) is a validated 14-item self-report questionnaire commonly used to assess anhedonia (reduced ability to experience pleasure). Each of the 14 items is rated from 1 (strongly agree) to 4 (strongly disagree). Total scores range from 14 to 56, with higher scores indicating greater levels of anhedonia. SHAPS total score change from baseline at week 6 |
From baseline to end of treatment (Week 6).
|
|
Change in Beck Anxiety Inventory (BAI) Score.
Lasso di tempo: From baseline to end of treatment (Week 6).
|
Beck Anxiety Inventory (BAI) is a 21-item self-report questionnaire used to assess the severity of anxiety symptoms. Each item is scored on a scale from 0 (not at all) to 3 (severely), yielding a total score ranging from 0 to 63, with higher scores indicating greater anxiety severity. BAI total score change from baseline at week 6 |
From baseline to end of treatment (Week 6).
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Study Director, Xenon Pharmaceuticals Inc.
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- XPF-008-204
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .